Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valeria Leuci

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Stem Cells (Dayton, Ohio)|March 29, 2008
Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectorsMelania Tesio, Loretta Gammaitoni, Monica Gunetti, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 22, 2022
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapyCristina Chiriaco, Chiara Donini, Marco Cortese, et al.
Journal of Biotechnology|September 22, 2011
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectorsValeria Leuci, Giulia Mesiano, Loretta Gammaitoni, et al.
Oncoimmunology|November 6, 2018
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapyGiulia Mesiano, Giovanni Grignani, Erika Fiorino, et al.
British Journal of Haematology|September 26, 2022
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriersPaola Circosta, Chiara Donini, Susanna Gallo, et al.
Cancer Immunology, Immunotherapy : CII|November 2, 2024
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosisFederica Galvagno, Valeria Leuci, Annamaria Massa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2024
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplificationMarco Cortese, Erica Torchiaro, Alice D'Andrea, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 AntibodyMartina Sanlorenzo, Igor Vujic, Arianna Floris, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Stem Cells (Dayton, Ohio)|March 29, 2008
Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectorsMelania Tesio, Loretta Gammaitoni, Monica Gunetti, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 22, 2022
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapyCristina Chiriaco, Chiara Donini, Marco Cortese, et al.
Journal of Biotechnology|September 22, 2011
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectorsValeria Leuci, Giulia Mesiano, Loretta Gammaitoni, et al.
Oncoimmunology|November 6, 2018
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapyGiulia Mesiano, Giovanni Grignani, Erika Fiorino, et al.
British Journal of Haematology|September 26, 2022
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriersPaola Circosta, Chiara Donini, Susanna Gallo, et al.
Cancer Immunology, Immunotherapy : CII|November 2, 2024
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosisFederica Galvagno, Valeria Leuci, Annamaria Massa, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 19, 2024
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplificationMarco Cortese, Erica Torchiaro, Alice D'Andrea, et al.
Cancers|December 24, 2021
PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas-A Preclinical and Translational StudyYmera Pignochino, Giovanni Crisafulli, Giorgia Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-PD-1 AntibodyMartina Sanlorenzo, Igor Vujic, Arianna Floris, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriersMaja Todorovic, Giulia Mesiano, Loretta Gammaitoni, et al.
Pageof 3